NOTICE TO THE MARKET

Grupo Biotoscana announces hiring of Executive Vice-President of R&D

Montevideo, Uruguay, December 15, 2017. GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that has hired Ivan French as Executive Vice President of Research and Development.

Ivan French has a long career combining medicine and management, having been for example a Medical Team Leader at Medicines sans Frontiers, a clinical research fellow at Genzyme Corporation but also an investment banker with Morgan Stanley New York and most recently, the General Manager for Uber Uruguay. Ivan will lead GBT´s proprietary products development efforts, taking over the company´s research center in Argentina and its recently acquired DOSA research center. Together with Renato De Giorgi, head of Business Development and Daniel Flores, Sr. Science Advisor, Ivan will lead the company’s pipeline strategy. Ivan French has a Medical Doctor Degree (Magna cum Laude) from Universidad Austral and an MBA from Harvard Business School.

According to Mariano Garcia-Valiño, CEO of GBT, “Ivan will bring renewed efforts into our proprietary product and clinical development and enhance our abilities to reach further-up into the R&D chain into earlier development phases, where more promising products and rarer opportunities are available.”

Mr. French will be responsible for GBT´s clinical research teams, central regulatory teams and central pharmacovigilance teams, both legacy LKM and legacy DOSA.

GBT – Grupo Biotoscana.
Melissa Angelini
IR Manager
Tel.: +55 11 5090 5927
ir@grupobiotoscana.com

To access the PDF version, please click here.